Making best use of existing NKCC1/2 Blockers in Autism
Azosemide C 12 H 11 ClN 6 O 2 S 2 Source: https://pubchem.ncbi.nlm.nih.gov/compound/azosemide Today’s post may be of interest to those already using bumetanide for autism and for those considering doing so . It does go into the details, because they really do matter and does assume some prior knowledge from earlier posts. There has been a very thorough new paper published by a group at Johns Hopkins:- Off-Label Use of Bumetanide for Brain Disorders: An Overview It does cover all the usual issues and raises some points that have not been covered yet in this blog. One point is treating autism prenatally. This issue was studied twice in rats, and the recent study was sent to me by Dr Ben Ari. Short term treatment during pregnancy produced a permanent benefit. Maternal bumetanide treatment prevents the overgrowth in the VPA condition Brief maternal administration of bumetanide before birth restores low ...